West Pharmaceutical Services entered three long-term agreements with Daikyo Seiko effective July 14, 2026: an amended and restated technology exchange and cross-license, plus two distributorship agreements. The cross-license supports joint development and know-how sharing for closures, vials, syringes, and related components, with West holding exclusive rights outside Japan and Daikyo holding a non-exclusive license; it is largely royalty-free aside from fixed royalties on certain IP and technical information. West becomes the exclusive distributor of Daikyo products outside Japan, while Daikyo becomes a non-exclusive distributor of West products in Japan. Each agreement carries a 10-year term with customary early termination rights, aiming to deepen global collaboration and market reach.
Agreement 1: West Pharmaceutical Services Renews 10-Year Cross-License With Daikyo Seiko to Advance Drug Packaging
- Agreement type: Amended and Restated Technology Exchange and Crosslicense Agreement
- Counterparty: Daikyo Seiko
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 10 years
- Reason: Advance joint development and global commercialization of drug packaging and delivery components
Agreement 2: West Pharmaceutical Services Secures 10-Year Exclusive Distribution of Daikyo Products Outside Japan
- Agreement type: Exclusive Distributorship Agreement for Daikyo products outside Japan
- Counterparty: Daikyo Seiko
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 10 years
- Reason: Expand global distribution reach for Daikyo’s offerings
Agreement 3: Daikyo Seiko Named Non-Exclusive Distributor of West Products in Japan Under 10-Year Pact
- Agreement type: Non-Exclusive Distributorship Agreement for West products in Japan
- Counterparty: Daikyo Seiko
- Signed / Effective: Jul 14 2026 / Jul 14 2026
- Duration / Termination: 10 years
- Reason: Strengthen Japan market access and customer coverage for West products
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.